CD4 and B-cell chronic lymphocytic leukemia: Treatment of primary CLL cells with EVs carrying the major glycoprotein of the Epstein bar virus (EBV) (gp350), the central immune accessory molecule (CD40 ligand), and the immunodominant antigen of the human cytomegalovirus (CMV) (pp65) restored their antigen-presenting capacity and rendered them immunogenic to allogenic and autologous EBV- and CMV-specific CD4+ and CD8+ T-cells [113].